{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T20:49:59Z","timestamp":1785703799228,"version":"3.56.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ejim.2026.107110","type":"journal-article","created":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T20:01:56Z","timestamp":1785700916000},"page":"107110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Particle engineering, aerosol physics, and pulmonary deposition of single-inhaler triple ICS\/LABA\/LAMA therapies in obstructive airway diseases"],"prefix":"10.1016","author":[{"given":"Claudio","family":"Sorino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann Christian","family":"Virchow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Spanevello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Buscemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fulvio","family":"Braido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Scichilone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2026.107110_bib0001","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ejim.2020.02.023","article-title":"Inhalation therapy devices for the treatment of obstructive lung diseases: the history of inhalers towards the ideal inhaler","volume":"75","author":"Sorino","year":"2020","journal-title":"Eur J Intern Med"},{"issue":"11\u201312","key":"10.1016\/j.ejim.2026.107110_bib0002","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1080\/17476348.2023.2167715","article-title":"Clinical characteristics, treatment patterns and adherence in patients with asthma on multiple inhaler triple therapy: a review of findings","volume":"16","author":"Cazzola","year":"2022","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.ejim.2026.107110_bib0003","article-title":"Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease","volume":"12","author":"van Geffen","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ejim.2026.107110_bib0004","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2147\/COPD.S345263","article-title":"Beyond dual bronchodilation - triple therapy, when and why","volume":"17","author":"Cazzola","year":"2022","journal-title":"Int J Chronic Obstr Pulm Dis"},{"issue":"6","key":"10.1016\/j.ejim.2026.107110_bib0005","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.chest.2016.07.035","article-title":"Dilemmas, confusion and misconceptions related to small airways disease, small particle inhaled therapy and adherence","volume":"151","author":"Lavorini","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.ejim.2026.107110_bib0006","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.2147\/COPD.S175017","article-title":"Blood eosinophils and inhaled corticosteroids in patients with COPD: systematic review and meta-analysis","volume":"13","author":"Cheng","year":"2018","journal-title":"Int J Chronic Obstr Pulm Dis"},{"issue":"3","key":"10.1016\/j.ejim.2026.107110_bib0007","doi-asserted-by":"crossref","first-page":"185","DOI":"10.4046\/trd.2020.0026","article-title":"Blood eosinophil counts in chronic obstructive pulmonary disease: a biomarker of inhaled corticosteroid effects","volume":"83","author":"Singh","year":"2020","journal-title":"Tuberc Respir Dis (Seoul)"},{"issue":"2","key":"10.1016\/j.ejim.2026.107110_bib0008","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S2213-2600(18)30006-7","article-title":"Predictors of exacerbation risk and response to budesonide in patients with COPD: a post-hoc analysis of three randomised trials","volume":"6","author":"Bafadhel","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"7","key":"10.1016\/j.ejim.2026.107110_bib0009","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1164\/rccm.201209-1739PP","article-title":"\u03b22-agonist therapy in lung disease","volume":"187","author":"Cazzola","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ejim.2026.107110_bib0010","article-title":"Long-acting maintenance pharmacotherapy in chronic obstructive pulmonary disease","volume":"1","author":"Harrison","year":"2019","journal-title":"Respir Med X"},{"issue":"164","key":"10.1016\/j.ejim.2026.107110_bib0011","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0196-2021","article-title":"The impact of long-acting muscarinic antagonists on mucus hypersecretion and cough in chronic obstructive pulmonary disease: a systematic review","volume":"31","author":"Calzetta","year":"2022","journal-title":"Eur Respir Rev"},{"issue":"10048","key":"10.1016\/j.ejim.2026.107110_bib0012","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S0140-6736(16)31354-X","article-title":"Single inhaler triple therapy versus inhaled corticosteroid plus long-acting beta2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial","volume":"388","author":"Singh","year":"2016","journal-title":"Lancet"},{"issue":"10082","key":"10.1016\/j.ejim.2026.107110_bib0013","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/S0140-6736(17)30188-5","article-title":"Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial","volume":"389","author":"Vestbo","year":"2017","journal-title":"Lancet"},{"issue":"10125","key":"10.1016\/j.ejim.2026.107110_bib0014","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/S0140-6736(18)30206-X","article-title":"Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial","volume":"391","author":"Papi","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2026.107110_bib0015","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2147\/COPD.S196383","article-title":"Extrafine triple therapy delays COPD clinically important deterioration vs ICS\/LABA, LAMA, or LABA\/LAMA","volume":"14","author":"Singh","year":"2019","journal-title":"Int J Chronic Obstr Pulm Dis"},{"issue":"1","key":"10.1016\/j.ejim.2026.107110_bib0016","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1916046","article-title":"Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD (ETHOS)","volume":"383","author":"Rabe","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ejim.2026.107110_bib0017","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1164\/rccm.202006-2618OC","article-title":"Reduced all-cause mortality in the ETHOS trial of budesonide\/glycopyrrolate\/formoterol for COPD","volume":"203","author":"Martinez","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"18","key":"10.1016\/j.ejim.2026.107110_bib0018","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","article-title":"Once-daily single-inhaler triple versus dual therapy in patients with COPD (IMPACT)","volume":"378","author":"Lipson","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ejim.2026.107110_bib0019","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1164\/rccm.201911-2207OC","article-title":"Reduction in all-cause mortality with fluticasone furoate\/umeclidinium\/vilanterol in patients with COPD","volume":"201","author":"Lipson","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"10210","key":"10.1016\/j.ejim.2026.107110_bib0020","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/S0140-6736(19)32215-9","article-title":"Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials","volume":"394","author":"Virchow","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ejim.2026.107110_bib0021","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S2213-2600(25)00457-6","article-title":"Budesonide-glycopyrronium-formoterol fumarate dihydrate in uncontrolled asthma (KALOS and LOGOS): twin multicentre, double-blind, double-dummy, parallel-group, randomised, phase 3 trials","volume":"14","author":"Papi","year":"2026","journal-title":"Lancet Respir Med"},{"issue":"10","key":"10.1016\/j.ejim.2026.107110_bib0022","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S2213-2600(20)30190-9","volume":"8","author":"Kerstjens","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ejim.2026.107110_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.106021","article-title":"Fixed-dose combination of indacaterol\/glycopyrronium\/mometasone furoate once-daily versus salmeterol\/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: a randomised, phase IIIb, non-inferiority study (ARGON)","volume":"170","author":"Gessner","year":"2020","journal-title":"Respir Med"},{"issue":"1","key":"10.1016\/j.ejim.2026.107110_bib0024","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S2213-2600(20)30389-1","article-title":"Efficacy and safety of once-daily single-inhaler triple therapy (FF\/UMEC\/VI) versus FF\/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial","volume":"9","author":"Lee","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.ejim.2026.107110_bib0025","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1089\/jamp.2016.1359","article-title":"Lung deposition of the dry powder fixed combination beclometasone dipropionate plus formoterol fumarate using NEXThaler device in healthy subjects, asthmatic patients, and COPD patients","volume":"31","author":"Virchow","year":"2018","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"10.1016\/j.ejim.2026.107110_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2020.105472","article-title":"Pulmonary deposition of budesonide\/glycopyrronium\/formoterol fumarate dihydrate MDI formulated using co-suspension delivery technology in healthy male subjects","volume":"153","author":"Israel","year":"2020","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.ejim.2026.107110_bib0027","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2147\/COPD.S274846","article-title":"Consistent pulmonary drug delivery with whole lung deposition using the Aerosphere inhaler: a review of the evidence","volume":"16","author":"Usmani","year":"2021","journal-title":"Int J Chronic Obstr Pulm Dis"},{"issue":"2","key":"10.1016\/j.ejim.2026.107110_bib0028","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1089\/jamp.2015.1270","article-title":"Deposition mechanisms in the lung","volume":"29","author":"Darquenne","year":"2016","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"10.1016\/j.ejim.2026.107110_bib0029","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.rmed.2016.05.006","article-title":"The prevalence of small airways disease in adult asthma: a systematic literature review","volume":"116","author":"Usmani","year":"2016","journal-title":"Respir Med"},{"issue":"5","key":"10.1016\/j.ejim.2026.107110_bib0030","first-page":"596","article-title":"Physical and functional remodelling of the airway wall in patients with severe, uncontrolled asthma","volume":"65","author":"Contoli","year":"2010","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.ejim.2026.107110_bib0031","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1089\/jamp.2009.0772","article-title":"Lung deposition of BDP\/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients","volume":"23","author":"De Backer","year":"2010","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"5","key":"10.1016\/j.ejim.2026.107110_bib0032","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.anai.2025.12.016","article-title":"Relative particle size and distribution of inhaled triple therapies","volume":"136","author":"Lipworth","year":"2026","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.ejim.2026.107110_bib0033","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.rmed.2017.09.012","article-title":"Co-suspension delivery technology in pressurized metered-dose inhalers for multi-drug dosing in the treatment of respiratory diseases","volume":"134","author":"Ferguson","year":"2018","journal-title":"Respir Med"},{"issue":"10","key":"10.1016\/j.ejim.2026.107110_bib0034","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16101334","article-title":"In vitro analysis of aerodynamic properties and Co-deposition of a fixed-dose combination of fluticasone furoate, umeclidinium bromide, and vilanterol trifenatate","volume":"16","author":"Maneechotesuwan","year":"2024","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.ejim.2026.107110_bib0035","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1089\/jamp.2022.29072.bll","article-title":"Imaging aerosol deposition with two-dimensional gamma scintigraphy","volume":"35","author":"Laube","year":"2022","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"3","key":"10.1016\/j.ejim.2026.107110_bib0036","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1089\/jamp.2010.0845","article-title":"Variation in the measurement of inhaled aerosol deposition using gamma scintigraphy","volume":"24","author":"Biddiscombe","year":"2011","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"Suppl 1","key":"10.1016\/j.ejim.2026.107110_bib0037","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1089\/jamp.2012.1Su3","article-title":"Validation of radiolabeling of drug formulations for aerosol deposition assessment of orally inhaled products","volume":"25","author":"Devadason","year":"2012","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"1","key":"10.1016\/j.ejim.2026.107110_bib0038","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1089\/jamp.2023.29077.jsf","article-title":"The use of single photon emission computed tomography in aerosol medicine","volume":"36","author":"Fleming","year":"2023","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"3","key":"10.1016\/j.ejim.2026.107110_bib0039","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1089\/jamp.2020.1601","article-title":"Predicting lung deposition of extrafine inhaled corticosteroid-containing fixed combinations in patients with chronic obstructive pulmonary disease using functional Respiratory imaging: an In silico study","volume":"34","author":"Usmani","year":"2021","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"1","key":"10.1016\/j.ejim.2026.107110_bib0040","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-026-45628-5","article-title":"Enhancing aerosol delivery in asthma and COPD: a comparison of MDI, valved holding chamber, and DPI systems using functional respiratory imaging (FRI)","volume":"16","author":"Nagel","year":"2026","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.ejim.2026.107110_bib0041","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s12931-023-02534-y","article-title":"Modeled small airways lung deposition of two fixed-dose triple therapy combinations assessed with in silico functional respiratory imaging","volume":"24","author":"Usmani","year":"2023","journal-title":"Respir Res"},{"key":"10.1016\/j.ejim.2026.107110_bib0042","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.2147\/COPD.S510214","article-title":"In silico lung deposition profiles of three single-inhaler triple therapies in patients with COPD using functional respiratory imaging","volume":"20","author":"Singh","year":"2025","journal-title":"Int J Chronic Obstr Pulm Dis"},{"issue":"9","key":"10.1016\/j.ejim.2026.107110_bib0043","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15092206","article-title":"Evaluation of different doses in inhaled therapy: a comprehensive analysis","volume":"15","author":"Lopez-Campos","year":"2023","journal-title":"Pharmaceutics"},{"issue":"5","key":"10.1016\/j.ejim.2026.107110_bib0044","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1183\/09031936.00074905","article-title":"Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma","volume":"28","author":"Derendorf","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ejim.2026.107110_bib0045","article-title":"Biophysical model to predict lung delivery from a dual bronchodilator dry-powder inhaler","volume":"1","author":"Dolovich","year":"2019","journal-title":"Int J Pharm X"},{"issue":"4","key":"10.1016\/j.ejim.2026.107110_bib0046","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s13318-021-00689-x","article-title":"Population pharmacokinetic analysis of indacaterol\/glycopyrronium\/mometasone furoate after administration of combination therapies using the breezhaler\u00ae device in patients with asthma","volume":"46","author":"Bartels","year":"2021","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"2","key":"10.1016\/j.ejim.2026.107110_bib0047","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1089\/jamp.2015.1220","article-title":"Effect of flow rate on In vitro aerodynamic performance of NEXThaler(\u00ae) in comparison with Diskus(\u00ae) and Turbohaler(\u00ae) dry powder inhalers","volume":"29","author":"Buttini","year":"2016","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"1","key":"10.1016\/j.ejim.2026.107110_bib0048","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12890-021-01430-9","article-title":"Inspiratory flow profile and usability of the NEXThaler, a multidose dry powder inhaler, in asthma and COPD","volume":"21","author":"Chetta","year":"2021","journal-title":"BMC Pulm Med"},{"issue":"2","key":"10.1016\/j.ejim.2026.107110_bib0049","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/MCP.0000000000001043","article-title":"Utility of peak inspiratory flow measurement for dry powder inhaler use in chronic obstructive pulmonary disease","volume":"30","author":"Loh","year":"2024","journal-title":"Curr Opin Pulm Med"},{"issue":"2","key":"10.1016\/j.ejim.2026.107110_bib0050","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1089\/jam.1993.6.99","article-title":"The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers \u2014 Implications for in vitro testing","volume":"6","author":"Clark","year":"1993","journal-title":"J Aerosol Med"},{"issue":"1","key":"10.1016\/j.ejim.2026.107110_bib0051","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1183\/09031936.00024807","article-title":"Inspiratory flow rates at different levels of resistance in elderly COPD patients","volume":"31","author":"Janssens","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ejim.2026.107110_bib0052","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2147\/COPD.S353441","article-title":"Prospective evaluation of exacerbations associated with suboptimal peak inspiratory flow among stable outpatients with COPD","volume":"17","author":"Mahler","year":"2022","journal-title":"Int J Chronic Obstr Pulm Dis"},{"key":"10.1016\/j.ejim.2026.107110_bib0053","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.2147\/COPD.S380736","article-title":"Suboptimal peak inspiratory flow and critical inhalation errors are associated with higher COPD-related healthcare costs","volume":"17","author":"Leving","year":"2022","journal-title":"Int J Chronic Obstr Pulm Dis"},{"key":"10.1016\/j.ejim.2026.107110_bib0054","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2147\/COPD.S195438","article-title":"Prevalence and factors associated with suboptimal peak inspiratory flow rates in COPD","volume":"14","author":"Ghosh","year":"2019","journal-title":"Int J Chronic Obstr Pulm Dis"},{"key":"10.1016\/j.ejim.2026.107110_bib0055","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.2147\/COPD.S311178","article-title":"Prevalence and associated factors of suboptimal daily peak inspiratory flow and technique misuse of dry powder inhalers in outpatients with stable chronic airway diseases","volume":"16","author":"Ding","year":"2021","journal-title":"Int J Chronic Obstr Pulm Dis"},{"key":"10.1016\/j.ejim.2026.107110_bib0056","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.2147\/COPD.S404243","article-title":"Clinical implications of peak inspiratory flow in COPD: post hoc analyses of the TRONARTO study","volume":"18","author":"Mahler","year":"2023","journal-title":"Int J Chronic Obstr Pulm Dis"},{"key":"10.1016\/j.ejim.2026.107110_bib0057","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.105952","article-title":"Current place of impulse oscillometry in the assessment of pulmonary diseases","volume":"170","author":"Bednarek","year":"2020","journal-title":"Respir Med"},{"issue":"3","key":"10.1016\/j.ejim.2026.107110_bib0058","doi-asserted-by":"crossref","first-page":"00092","DOI":"10.1183\/23120541.00092-2020","article-title":"Prediction of air trapping or pulmonary hyperinflation by forced spirometry in COPD patients: results from COSYCONET","volume":"6","author":"Alter","year":"2020","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.ejim.2026.107110_bib0059","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2024.107532","article-title":"Small airways in asthma: from inflammation and pathophysiology to treatment response","volume":"222","author":"Siora","year":"2024","journal-title":"Respir Med"},{"issue":"1","key":"10.1016\/j.ejim.2026.107110_bib0060","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12931-017-0710-y","article-title":"Critical inhaler errors in asthma and COPD: a systematic review of impact on health outcomes","volume":"19","author":"Usmani","year":"2018","journal-title":"Respir Res"},{"issue":"6","key":"10.1016\/j.ejim.2026.107110_bib0061","first-page":"499","article-title":"Effectiveness of same versus mixed asthma inhaler devices: a retrospective observational study in primary care","volume":"9","author":"Price","year":"2017","journal-title":"Allergy Asthma Immunol Res"},{"issue":"1","key":"10.1016\/j.ejim.2026.107110_bib0062","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1136\/thoraxjnl-2019-213744","article-title":"Carbon footprint impact of the choice of inhalers for asthma and COPD","volume":"75","author":"Janson","year":"2020","journal-title":"Thorax"},{"issue":"8","key":"10.1016\/j.ejim.2026.107110_bib0063","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1080\/17425247.2023.2264184","article-title":"Metered dose inhalers in the transition to low GWP propellants: what we know and what is missing to make it happen","volume":"20","author":"Buttini","year":"2023","journal-title":"Expert Opin Drug Deliv"},{"issue":"2","key":"10.1016\/j.ejim.2026.107110_bib0064","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s11095-025-03830-6","article-title":"In-vitro evaluation of solution pressurised metered dose inhaler sprays with low-GWP propellants","volume":"42","author":"Duke","year":"2025","journal-title":"Pharm Res"},{"issue":"11","key":"10.1016\/j.ejim.2026.107110_bib0065","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1002\/jps.24167","article-title":"Developing an in vitro understanding of patient experience with hydrofluoroalkane-metered dose inhalers","volume":"103","author":"Doub","year":"2014","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.ejim.2026.107110_bib0066","article-title":"Artificial intelligence prediction of aerosol drug deposition in patient-specific COPD airways","volume":"678","author":"Chen","year":"2025","journal-title":"Int J Pharm"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620526004152?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620526004152?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T20:02:04Z","timestamp":1785700924000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620526004152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":66,"alternative-id":["S0953620526004152"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2026.107110","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Particle engineering, aerosol physics, and pulmonary deposition of single-inhaler triple ICS\/LABA\/LAMA therapies in obstructive airway diseases","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2026.107110","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Federation of Internal Medicine. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107110"}}